Guinness Asset Management LTD Purchases 8,624 Shares of Danaher Corporation $DHR

Key Points

• Guinness Asset Management LTD increased its stake in Danaher Corporation by 5.3% in Q1 after purchasing an additional 8,624 shares, bringing its total holdings to 171,960 shares valued at $35.25 million.
• A Director at Danaher, Teri List, sold 2,778 shares at an average price of $211.06, marking an 11.81% decrease in her position.
• Analysts have adjusted their price targets for Danaher, with the average price target now at $246.35 and an overall rating of "Moderate Buy" from 17 researchers.

Guinness Asset Management LTD boosted its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 5.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,960 shares of the conglomerate's stock after acquiring an additional 8,624 shares during the period. Guinness Asset Management LTD's holdings in Danaher were worth $35,253,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. eCIO Inc. acquired a new position in Danaher during the 1st quarter worth $131,000. Osterweis Capital Management Inc. raised its position in shares of Danaher by 26.0% during the first quarter. Osterweis Capital Management Inc. now owns 128,535 shares of the conglomerate's stock valued at $26,350,000 after buying an additional 26,494 shares during the last quarter. Modern Wealth Management LLC raised its position in shares of Danaher by 42.7% during the first quarter. Modern Wealth Management LLC now owns 1,521 shares of the conglomerate's stock valued at $312,000 after buying an additional 455 shares during the last quarter. Strs Ohio acquired a new position in shares of Danaher during the first quarter valued at about $48,467,000. Finally, Foresight Group Ltd Liability Partnership acquired a new position in shares of Danaher during the first quarter valued at about $11,515,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on DHR. UBS Group cut their price objective on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Evercore ISI cut their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Robert W. Baird upped their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a research report on Friday, July 18th. Guggenheim reaffirmed a "buy" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Seventeen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Danaher has an average rating of "Moderate Buy" and a consensus target price of $246.35.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 11.10% of the company's stock.

Danaher Price Performance

Shares of DHR traded down $1.81 during mid-day trading on Monday, hitting $188.24. 4,675,396 shares of the company traded hands, compared to its average volume of 4,143,512. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The business has a 50-day moving average of $201.21 and a 200 day moving average of $198.78. The stock has a market capitalization of $134.79 billion, a price-to-earnings ratio of 40.05, a PEG ratio of 2.65 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the firm earned $1.72 earnings per share. Danaher's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.7%. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.